RxDoctor Payments Data

Irma Rymers

Family · Stockton, CANPI 1184859142

Payments from drug & device makers

$8,815in general payments, 2019–2025

Across 254 payments — averaging $34.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Novo Nordisk$2K
  • Lilly USA, LLC$504
  • Abbott$391
  • Boehringer Ingelheim$361
  • Dexcom, Inc.$273
  • plus $1K from 18 others

What the payments were for

  • Speaking & faculty fees$4,28349%
  • Food & beverage$4,53251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,815 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin358$367,595
OzempicSemaglutide194$181,150
RybelsusSemaglutide72$108,335
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog103$40,888
TradjentaLinagliptin44$38,121
Fiasp FlextouchInsulin Aspart (Niacinamide)24$17,080
MounjaroTirzepatide17$15,966
Humalog Kwikpen U-100Insulin Lispro69$11,652
Janumet XrSitagliptin Phos/Metformin Hcl19$10,203
Lantus SolostarInsulin Glargine,hum.Rec.Anlog81$9,375
FarxigaDapagliflozin Propanediol13$8,583
Insulin Lispro Kwikpen U-100Insulin Lispro32$6,926
Novolog FlexpenInsulin Aspart32$6,495
Nano 2nd Gen Pen NeedlePen Needle, Diabetic75$4,422
Ultra-Fine Short Pen NeedlePen Needle, Diabetic32$2,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$361$405,717402 claims
Novo NordiskOzempic, Rybelsus$1,808$289,484266 claims
Lilly USA, LLCMounjaro$504$15,96617 claims
MerckJanumet Xr$43$10,20319 claims
AstraZenecaFarxiga$165$8,58313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →